Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3C kidney transplant immunosuppression study
2008-008553-27Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Nov 2009
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alemtuzumab, basiliximab, sirolimus and tacrolimus in kidney transplant (4 arms), sponsored by University of Oxford. Primary endpoints: Incidence of acute rejection at 6 months post-transplantation and Transplant function by estimated glomerular filtration rate. Status: unknown.
02
Drugs
alemtuzumabbasiliximabsirolimustacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2008-008553-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008553-27.